Source link : https://www.newshealth.biz/health-news/potential-cure-for-early-brca-mutated-breast-cancer/
British investigators have demonstrated a “potentially curative” neoadjuvant regimen for early-stage germline BRCA 1/2–mutated breast cancer. In a small trial, 39 patients randomized to the regimen — a combination of standard chemotherapy with the poly(ADP-ribose)polymerase (PARP) inhibitor olaparib — were alive at 3 years vs 39 of 45 (87%) randomized to chemotherapy alone. “A remarkable […]
Author : News Health
Publish date : 2024-05-02 12:36:18
Copyright for syndicated content belongs to the linked Source.